Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.
Also called NCT05918861
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,000 participants
- Registry
-
NCT05918861
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Puerto Rico
- Registry status
- Recruiting
Technical summary
Registry record NCT05918861. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-03 (actual); primary completion 2027-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
- Acronym
- dal-GenE-2
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Dalcetrapib
- Intervention (Drug)
- Placebo
- Lead sponsor
- DalCor Pharmaceuticals
- Collaborator
- The Montreal Health Innovations Coordinating Center (MHICC)
Record details
- Record id
cardio:ct-nct05918861- Content hash
a75d8b37d608573cd6c0265a72c0e9ac554bb0a79f6de611e85569cd418df3b0